Endocrine therapy for advanced/metastatic breast cancer

Hematology/Oncology Clinics of North America

Volumn 27, Issue 4, 2013, Pages 715-736

  Schiavon, Gaia ^a,b   Smith, Ian E ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Advanced; Breast cancer; Endocrine resistance; Endocrine therapy; Metastatic

Indexed keywords

ABIRATERONE ACETATE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE INHIBITOR; ARZOXIFENE; BUPARLISIB; DROLOXIFENE; ENTINOSTAT; ESTRADIOL; ESTROGEN; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; GESTAGEN; GONADORELIN DERIVATIVE; GOSERELIN; IDOXIFENE; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDROXYPROGESTERONE; MEGESTROL ACETATE; PLACEBO; PREDNISONE; TAMOXIFEN; TEMSIROLIMUS; TOREMIFENE; TRASTUZUMAB;

BREAST CANCER; BREAST METASTASIS; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FLUID RETENTION; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERGLYCEMIA; LOW DRUG DOSE; MUSCULOSKELETAL PAIN; OVARIECTOMY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR FLARE; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VOMITING; WEIGHT GAIN;

ADVANCED; BREAST CANCER; ENDOCRINE RESISTANCE; ENDOCRINE THERAPY; METASTATIC;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; NEOPLASM STAGING; OVARIECTOMY; PROGESTINS; PROTEIN KINASE INHIBITORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84881317897     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.05.004     Document Type: Review

References (103)

1. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896, 148(3803):104-107.
2. Kennedy B.J., Kelley R.M., White G., et al. Surgery as an adjunct to hormone therapy of breast cancer. Cancer 1957, 10:1055-1075.
3. Huggins C., Bergenstal D.M. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res 1952, 12:134-141.
4. Fracchia A.A., Randall H.T., Farrow J.H. The results of adrenalectomy in advanced breast cancer in 500 consecutive patients. Surg Gynecol Obstet 1967, 125:747-756.
5. Harrold B.P., Cates J.E., James J.A. Treatment of advanced breast cancer by trans-sphenoidal hypophysectomy. Br J Cancer 1968, 22:19-31.
6. Jensen E.V., Jacobson H.I., Smith S., et al. The use of estrogen antagonists in hormone receptor studies. Gynecol Invest 1972, 3:108-123.
7. McGuire W.L. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978, 5:428-433.
8. Pritchard K.I. Endocrine therapy of advanced disease: analysis and implications of the existing data. Clin Cancer Res 2003, 9:460S-467S.
9. Cole M.P., Jones C.T., Todd I.D. Anew anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 1971, 25:270-275.
10. Litherland S., Jackson I.M. Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 1988, 15:183-194.
11. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
12. Jordan V.C. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 1995, 35:195-211.
13. Ingle J.N., Ahmann D.L., Green S.J., et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. NEngl J Med 1981, 304:16-21.
14. Robertson J.F. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev 2004, 30:695-706.
15. Gill P.G., Gebski V., Snyder R., et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol 1993, 4:741-744.
16. Ingle J.N., Ahmann D.L., Green S.J., et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 1982, 5:155-160.
17. Morgan L.R. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol 1985, 12:43-47.
18. Paterson A.H., Hanson J., Pritchard K.I., et al. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. Semin Oncol 1990, 17:52-62.
19. Buchanan R.B., Blamey R.W., Durrant K.R., et al. Arandomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. JClin Oncol 1986, 4:1326-1330.
20. Ingle J.N., Krook J.E., Green S.J., et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. JClin Oncol 1986, 4:178-185.
21. Pyrhonen S., Ellmen J., Vuorinen J., et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999, 56:133-143.
22. Johnston S.R. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res 2001, 7:4376s-4387s. [discussion: 4411s-2s].
23. Buzdar A., Hayes D., El-Khoudary A., et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 2002, 73:161-175.
24. Deshmane V., Krishnamurthy S., Melemed A.S., et al. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. JClin Oncol 2007, 25:4967-4973.
25. Barrios C., Forbes J.F., Jonat W., et al. The sequential use of endocrine treatment for advanced breast cancer: where are we?. Ann Oncol 2012, 23:1378-1386.
26. Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. NEngl J Med 2003, 348:2431-2442.
27. Jonat W., Howell A., Blomqvist C., et al. Arandomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996, 32A:404-412.
28. Buzdar A., Jonat W., Howell A., et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. JClin Oncol 1996, 14:2000-2011.
29. Buzdar A.U., Jonat W., Howell A., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998, 83:1142-1152.
30. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. JClin Oncol 1998, 16:453-461.
31. Goss P.E., Winer E.P., Tannock I.F., et al. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. JClin Oncol 1999, 17:52-63.
32. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. JClin Oncol 2000, 18:1399-1411.
33. Gershanovich M., Chaudri H.A., Campos D., et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998, 9:639-645.
34. Buzdar A., Douma J., Davidson N., et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. JClin Oncol 2001, 19:3357-3366.
35. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. JClin Oncol 2000, 18:3758-3767.
36. Bonneterre J., Thurlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. JClin Oncol 2000, 18:3748-3757.
37. Bonneterre J., Buzdar A., Nabholtz J.M., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001, 92:2247-2258.
38. Nabholtz J.M., Bonneterre J., Buzdar A., et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003, 39:1684-1689.
39. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. JClin Oncol 2003, 21:2101-2109.
40. Paridaens R.J., Dirix L.Y., Beex L.V., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. JClin Oncol 2008, 26:4883-4890.
41. Ferretti G., Bria E., Giannarelli D., et al. Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer 2006, 94:1789-1796.
42. Thurlimann B., Robertson J.F., Nabholtz J.M., et al. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003, 39:2310-2317.
43. Bachelot T., Bourgier C., Cropet C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. JClin Oncol 2012, 30:2718-2724.
44. Miller W.R., Bartlett J., Brodie A.M., et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?. Oncologist 2008, 13:829-837.
45. Cardoso F., Costa A., Norton L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21:242-252.
46. Bertelli G., Garrone O., Merlano M., et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005, 69:471-477.
47. Lonning P.E., Bajetta E., Murray R., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. JClin Oncol 2000, 18:2234-2244.
48. Chia S., Gradishar W., Mauriac L., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. JClin Oncol 2008, 26:1664-1670.
49. Johnston S. Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor - First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747), European Breast Cancer Conference. Eur J Cancer 2012, (Suppl 2).
50. Howell A., Robertson J.F., Abram P., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. JClin Oncol 2004, 22:1605-1613.
51. Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. JClin Oncol 2002, 20:3386-3395.
52. Howell A., Robertson J.F., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. JClin Oncol 2002, 20:3396-3403.
53. Robertson J.F., Osborne C.K., Howell A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003, 98:229-238.
54. Pippen J. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: a prospective combined survival analysis of two multicenter trials. Breast Cancer Res Treat 2003, 39(9):1228-1233.
55. Robertson J.F. Fulvestrant (Faslodex) - how to make a good drug better. Oncologist 2007, 12:774-784.
56. Pritchard K.I., Rolski J., Papai Z., et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat 2010, 123:453-461.
57. Di Leo A., Jerusalem G., Petruzelka L., et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. JClin Oncol 2010, 28:4594-4600.
58. Di Leo A. Final analysis of overall survival for the phase III CONFIRM Trial: fulvestrant 500 mg versus 250 mg. San Antonio Breast Cancer Symposium. Cancer Res 2012, (Suppl 3).
59. Robertson J.F., Llombart-Cussac A., Rolski J., et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. JClin Oncol 2009, 27:4530-4535.
60. Osborne C.K., Coronado-Heinsohn E.B., Hilsenbeck S.G., et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. JNatl Cancer Inst 1995, 87:746-750.
61. Mehta R.S., Barlow W.E., Albain K.S., et al. Combination anastrozole and fulvestrant in metastatic breast cancer. NEngl J Med 2012, 367:435-444.
62. Bergh J., Jonsson P.E., Lidbrink E.K., et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. JClin Oncol 2012, 30:1919-1925.
63. Allegra J.C., Kiefer S.M. Mechanisms of action of progestational agents. Semin Oncol 1985, 12:3-5.
64. Lonning P.E. Aromatase inhibitors and inactivators for breast cancer therapy. Drugs Aging 2002, 19:277-298.
65. Guerrero-Zotano A. Endocrine therapy for advanced breast cancer: beyond tamoxifen and aromatase inhibitors. Curr Cancer Ther Rev 2010, 6:51-61.
66. Lundgren S. Progestins in breast cancer treatment. A review. Acta Oncol 1992, 31:709-722.
67. Sedlacek S.M. An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol 1988, 15:3-13.
68. Cruz J.M., Muss H.B., Brockschmidt J.K., et al. Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy. Semin Oncol 1990, 17:63-67.
69. Carlini P., Bria E., Giannarelli D., et al. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer 2005, 104:1335-1342.
70. Ellis M.J., Gao F., Dehdashti F., et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009, 302:774-780.
71. Miller T.W., Balko J.M., Arteaga C.L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. JClin Oncol 2011, 29:4452-4461.
72. Rudolf J., Boulay A., Zumstein-Mecker S., et al. The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001with the aromatase inhibitor letrozole in breast carcinomas. Proc Am Assoc Cancer Res 2004.
73. deGraffenried L.A., Friedrichs W.E., Russell D.H., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004, 10:8059-8067.
74. Baselga J., Fumoleau P., Gil M., et al. Phase II, 3 arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Preliminary results, ASCO Annual Meeting Proceedings. JClin Oncol 2004, 22(Suppl 14):544.
75. Wolff A.C., Lazar A.A., Bondarenko I., et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. JClin Oncol 2013, 31:195-202.
76. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. NEngl J Med 2012, 366:520-529.
77. Piccart M, Baselga J, Noguchi S, etal. Final progression-free survival analysis of BOLERO-2: a Phase III trial of everolimus for postmenopausal women with advanced breast cancer, San Antonio Breast Cancer Symposium. San Antonio, TX, December 4-8, 2012.
78. Mayer I. SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC). ASCO Annual Meeting. J Clin Oncol, 2012.
79. Nagarai G. A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer. ASCO Annual Meeting. J Clin Oncol, 2012.
80. Klein P. Characterization of the overall survival benefit in ENCORE 301, a randomized placebo-controlled phase II study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer, ASCO Annual Meeting. J Clin Oncol. 2012.
81. Basu B. Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor- (ER) or androgen receptor (AR) -positive advanced breast carcinoma resistant to standard endocrine therapies, ASCO Annual Meeting. J Clin Oncol 2011.
82. O'Shaughnessy J: Randomized phase II open-label study of abiraterone acetate (AA) plus low-dose prednisone (P) with or without exemestane (E) in postmenopausal women with ER+ metastatic breast cancer (MBC) progressing after letrozole or anastrozole therapy, ASCO Annual Meeting. J Clin Oncol 2012.
83. Mueller H., Flury N., Eppenberger-Castori S., et al. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000, 89:384-388.
84. Kaufman B., Mackey J.R., Clemens M.R., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. JClin Oncol 2009, 27:5529-5537.
85. Osborne C.K., Neven P., Dirix L.Y., et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011, 17:1147-1159.
86. Cristofanilli M., Valero V., Mangalik A., et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010, 16:1904-1914.
87. Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. JClin Oncol 2009, 27:5538-5546.
88. Huober J., Fasching P.A., Barsoum M., et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2012, 21:27-33.
89. Pritchard K.I., Thomson D.B., Myers R.E., et al. Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 1980, 64:787-796.
90. Sawka C.A., Pritchard K.I., Shelley W., et al. Arandomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res Treat 1997, 44:211-215.
91. Crump M., Sawka C.A., DeBoer G., et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 1997, 44:201-210.
92. Burger C.W., Prinssen H.M., Kenemans P. LHRH agonist treatment of breast cancer and gynecological malignancies: a review. Eur J Obstet Gynecol Reprod Biol 1996, 67:27-33.
93. Taylor C.W., Green S., Dalton W.S., et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. JClin Oncol 1998, 16:994-999.
94. Klijn J.G., Seynaeve C., Beex L., et al. Combined treatment with buserelin (LHRH A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer: preliminary results of EORTC study 10881. Proc Am Soc Clin Oncol 1996.
95. Klijn J., Seynaeve C., Beex L., et al. Combined estrogen suppression and receptor blockade by buserelin and tamoxifen in premenopausal metastatic breast cancer: preliminary results of a 3-arm randomized study (EORTC 10881). Eur J Cancer 1996, 32A:49.
96. Jonat W., Kaufmann M., Blamey R.W., et al. Arandomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer 1995, 31A:137-142.
97. Boccardo F., Rubagotti A., Perrotta A., et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 1994, 5:337-342.
98. Klijn J., Blamey R., Boccardo F., et al. Anew standard treatment for advanced premenopausal breast cancer: a meta-analysis of the Combined Hormonal Agent Trialists' group (CHAT). Eur J Cancer 1998, 34(Suppl 5):S90.
99. Carlson R.W., Theriault R., Schurman C.M., et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. JClin Oncol 2010, 28:3917-3921.
100. Roche H, Delozier T, Chieze S, etal. Anastrozole and goserelin combination as first treatment for premenopausal receptor positive advanced or metastatic breast cancer: a phase II trial. ASCO Ann Meeting, Proc J Clin Oncol, 2009.
101. Cheung K.L., Agrawal A., Folkerd E., et al. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. Eur J Cancer 2010, 46:2936-2942.
102. Forward D.P., Cheung K.L., Jackson L., et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004, 90:590-594.
103. Bartsch R., Bago-Horvath Z., Berghoff A., et al. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur J Cancer 2012, 48:1932-1938.